Egetis Therapeutics AB (publ) (STO:EGTX)
Sweden
· Delayed Price · Currency is SEK 5.60
+0.44 (8.53%)
Mar 9, 2026, 5:29 PM CET
Egetis Therapeutics AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 62.4 | 46.1 | 57.6 | 22.6 | 38.2 | Upgrade
|
| Revenue | 62.4 | 46.1 | 57.6 | 22.6 | 38.2 | Upgrade
|
| Revenue Growth (YoY) | 35.36% | -19.96% | 154.87% | -40.84% | -6.05% | Upgrade
|
| Cost of Revenue | 50 | 11.6 | 11 | 142.6 | 96.6 | Upgrade
|
| Gross Profit | 12.4 | 34.5 | 46.6 | -120 | -58.4 | Upgrade
|
| Selling, General & Admin | 201 | 215.3 | 172.8 | 74.3 | 44.6 | Upgrade
|
| Research & Development | 158.3 | 146.2 | 194 | - | - | Upgrade
|
| Other Operating Expenses | -6.9 | -5.2 | -8.9 | - | -0.3 | Upgrade
|
| Operating Expenses | 352.4 | 356.3 | 357.9 | 77 | 46.8 | Upgrade
|
| Operating Income | -340 | -321.8 | -311.3 | -197 | -105.2 | Upgrade
|
| Interest Expense | -22.7 | -17.6 | -4.2 | -0.1 | -0.2 | Upgrade
|
| Interest & Investment Income | 13.3 | 6.9 | 4.9 | 0.9 | 0.1 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -6.3 | -13.4 | 2.4 | 0.6 | Upgrade
|
| Other Non Operating Income (Expenses) | 7.3 | -4.5 | -2.8 | - | 0.2 | Upgrade
|
| Pretax Income | -342.1 | -343.3 | -326.8 | -193.8 | -104.5 | Upgrade
|
| Income Tax Expense | 0.4 | 0.3 | 0.1 | - | - | Upgrade
|
| Net Income | -342.5 | -343.6 | -326.9 | -193.8 | -104.5 | Upgrade
|
| Net Income to Common | -342.5 | -343.6 | -326.9 | -193.8 | -104.5 | Upgrade
|
| Shares Outstanding (Basic) | 368 | 307 | 257 | 194 | 180 | Upgrade
|
| Shares Outstanding (Diluted) | 368 | 311 | 260 | 194 | 180 | Upgrade
|
| Shares Change (YoY) | 18.43% | 19.57% | 33.86% | 7.97% | 166.96% | Upgrade
|
| EPS (Basic) | -0.93 | -1.12 | -1.27 | -1.00 | -0.58 | Upgrade
|
| EPS (Diluted) | -0.93 | -1.12 | -1.30 | -1.00 | -0.60 | Upgrade
|
| Free Cash Flow | -268.5 | -227.9 | -278.4 | -173.5 | -130.3 | Upgrade
|
| Free Cash Flow Per Share | -0.73 | -0.73 | -1.07 | -0.89 | -0.72 | Upgrade
|
| Gross Margin | 19.87% | 74.84% | 80.90% | - | -152.88% | Upgrade
|
| Operating Margin | -544.87% | -698.05% | -540.45% | -871.68% | -275.39% | Upgrade
|
| Profit Margin | -548.88% | -745.34% | -567.53% | -857.52% | -273.56% | Upgrade
|
| Free Cash Flow Margin | -430.29% | -494.36% | -483.33% | -767.70% | -341.10% | Upgrade
|
| EBITDA | -308.53 | -319.1 | -310.2 | -195.8 | -104 | Upgrade
|
| EBITDA Margin | - | - | - | - | -272.25% | Upgrade
|
| D&A For EBITDA | 31.47 | 2.7 | 1.1 | 1.2 | 1.2 | Upgrade
|
| EBIT | -340 | -321.8 | -311.3 | -197 | -105.2 | Upgrade
|
| EBIT Margin | - | - | - | - | -275.39% | Upgrade
|
| Revenue as Reported | - | - | - | 22.6 | 38.5 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.